{ "labelLang" : "hun", "responseDate" : "2024-03-29 13:46", "content" : { "otype" : "BookChapter", "mtid" : 26103545, "status" : "VALIDATED", "published" : true, "comment" : "Department of Medicine, Medical College of South Carolina, University Hospital, Charleston SC, United States \n Diabetes Center of Excellence, University of Oklahoma Health Sciences Center, Oklahoma City,OK, United States \n University of South Carolina, Division of Endocrinology, Diabetes and Medical Genetics, Charleston,SC, United States \n Departments of Microbiology and Immunology Bioengineering, United States \n Cholesterol Clinic, Endocrinology, Diabetes and Medical Genetics, Medical University of South Carolina, United States \n Nutrition Support Team, Clinical Chemistry, Immunology and Serology, and Microbiology, United States \n Cholesterol and Lipid Clinics, Ralph H. Johnson VA Medical Center, Charleston, SC, United States \n Department of Medicine, Medical University of South Carolina, Charleston SC, United States \n Cited By :3 \n Export Date: 21 November 2023 \n Correspondence Address: Colwell, J.A.; Department of Medicine, , Charleston SC, United States", "unhandledTickets" : 0, "oldTimestamp" : "2016-09-29T10:39:00.000+0000", "deleted" : false, "oldId" : 16103545, "lastRefresh" : "2023-12-02T17:23:28.632+0000", "lastModified" : "2019-12-15T15:29:41.694+0000", "created" : "2016-09-29T09:54:35.000+0000", "creator" : { "otype" : "Admin", "mtid" : 10019567, "link" : "/api/admin/10019567", "label" : "Sifter Viktória (PPKE ITK admin 5)", "familyName" : "Sifter", "givenName" : "Viktória", "published" : true, "oldId" : 10019567, "snippet" : true }, "lastDuplumOK" : "2023-12-02T17:22:09.055+0000", "lastDuplumSearch" : "2023-12-02T17:22:09.055+0000", "adminApproved" : "2016-09-29T10:39:00.000+0000", "adminApprover" : { "otype" : "Admin", "mtid" : 10019567, "link" : "/api/admin/10019567", "label" : "Sifter Viktória (PPKE ITK admin 5)", "familyName" : "Sifter", "givenName" : "Viktória", "published" : true, "oldId" : 10019567, "snippet" : true }, "validated" : "2019-12-15T15:29:41.714+0000", "validator" : { "otype" : "Admin", "mtid" : 10015544, "link" : "/api/admin/10015544", "label" : "Csajbók Edit (SE_KK_Admin5_CSE, admin)", "familyName" : "Csajbók", "givenName" : "Edit", "published" : true, "oldId" : 10015544, "snippet" : true }, "core" : false, "citation" : true, "publicationPending" : false, "type" : { "otype" : "PublicationType", "mtid" : 25, "link" : "/api/publicationtype/25", "label" : "Könyvrészlet", "code" : 25, "otypeName" : "BookChapter", "listPosition" : 2, "published" : true, "oldId" : 25, "snippet" : true }, "subType" : { "otype" : "SubType", "mtid" : 10000398, "link" : "/api/subtype/10000398", "label" : "Könyvfejezet (Könyvrészlet)", "name" : "Könyvfejezet", "nameEng" : "Chapter", "docType" : { "otype" : "PublicationType", "mtid" : 25, "link" : "/api/publicationtype/25", "label" : "Könyvrészlet", "code" : 25, "otypeName" : "BookChapter", "listPosition" : 2, "published" : true, "oldId" : 25, "snippet" : true }, "listPosition" : 220, "published" : true, "oldId" : 10000398, "snippet" : true }, "category" : { "otype" : "Category", "mtid" : 1, "link" : "/api/category/1", "label" : "Tudományos", "published" : true, "oldId" : 1, "snippet" : true }, "languages" : [ { "otype" : "Language", "mtid" : 10002, "link" : "/api/language/10002", "label" : "Angol", "name" : "Angol", "nameEng" : "English", "published" : true, "oldId" : 2, "snippet" : true } ], "firstAuthor" : "Colwell, JA", "authorships" : [ { "otype" : "PersonAuthorship", "mtid" : 59977122, "link" : "/api/authorship/59977122", "label" : "Colwell, JA", "listPosition" : 1, "share" : 0.0, "first" : true, "last" : false, "familyName" : "Colwell", "givenName" : "JA", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "oldId" : 123299243, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 59977123, "link" : "/api/authorship/59977123", "label" : "Lyons, TJ", "listPosition" : 2, "share" : 0.0, "first" : false, "last" : false, "familyName" : "Lyons", "givenName" : "TJ", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "oldId" : 123299242, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 59977124, "link" : "/api/authorship/59977124", "label" : "Klein, RL", "listPosition" : 3, "share" : 0.0, "first" : false, "last" : false, "familyName" : "Klein", "givenName" : "RL", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "oldId" : 123299241, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 59977125, "link" : "/api/authorship/59977125", "label" : "Lopes-Virella, MF", "listPosition" : 4, "share" : 0.0, "first" : false, "last" : false, "familyName" : "Lopes-Virella", "givenName" : "MF", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "oldId" : 123299240, "snippet" : true }, { "otype" : "PersonAuthorship", "mtid" : 59977126, "link" : "/api/authorship/59977126", "label" : "Jokl, RJ", "listPosition" : 5, "share" : 0.0, "first" : false, "last" : true, "familyName" : "Jokl", "givenName" : "RJ", "authorTyped" : true, "editorTyped" : false, "otherTyped" : false, "type" : { "otype" : "AuthorshipType", "mtid" : 1, "link" : "/api/authorshiptype/1", "label" : "Szerző", "code" : 0, "published" : true, "oldId" : 0, "snippet" : true }, "published" : false, "oldId" : 123299239, "snippet" : true } ], "title" : "Atherosclerosis and Thrombosis in Diabetes Mellitus: New Aspects of Pathogenesis", "identifiers" : [ { "otype" : "PublicationIdentifier", "mtid" : 11574594, "link" : "/api/publicationidentifier/11574594", "label" : "DOI: 10.1016/B978-0-323-04145-4.50012-0", "source" : { "otype" : "PlainSource", "mtid" : 6, "link" : "/api/publicationsource/6", "label" : "DOI", "type" : { "otype" : "PublicationSourceType", "mtid" : 10001, "link" : "/api/publicationsourcetype/10001", "label" : "DOI", "mayHaveOa" : true, "published" : true, "snippet" : true }, "name" : "DOI", "nameEng" : "DOI", "linkPattern" : "https://doi.org/@@@", "publiclyVisible" : true, "published" : true, "oldId" : 6, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "10.1016/B978-0-323-04145-4.50012-0", "realUrl" : "https://doi.org/10.1016/B978-0-323-04145-4.50012-0", "published" : false, "oldId" : 13411998, "snippet" : true }, { "otype" : "PublicationIdentifier", "mtid" : 11574593, "link" : "/api/publicationidentifier/11574593", "label" : "Scopus: 52149117740", "source" : { "otype" : "PlainSource", "mtid" : 3, "link" : "/api/publicationsource/3", "label" : "Scopus", "type" : { "otype" : "PublicationSourceType", "mtid" : 10003, "link" : "/api/publicationsourcetype/10003", "label" : "Indexelő adatbázis", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "Scopus", "linkPattern" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-@@@", "publiclyVisible" : true, "published" : true, "oldId" : 3, "snippet" : true }, "validState" : "IDENTICAL", "idValue" : "52149117740", "realUrl" : "http://www.scopus.com/record/display.url?origin=inward&eid=2-s2.0-52149117740", "published" : false, "oldId" : 13411997, "snippet" : true } ], "firstPage" : "89", "lastPage" : "113", "firstPageOrInternalIdForSort" : "89", "pageLength" : 25, "publishedYear" : 2008, "digital" : null, "printed" : null, "sourceYear" : 2016, "packet" : "612824", "foreignEdition" : null, "foreignLanguage" : true, "fullPublication" : true, "conferencePublication" : false, "nationalOrigin" : false, "missingAuthor" : false, "oaType" : "NONE", "oaCheckDate" : "2023-12-02", "oaFree" : false, "citationCount" : 0, "citationCountUnpublished" : 0, "citationCountWoOther" : 0, "independentCitCountWoOther" : 0, "doiCitationCount" : 0, "wosCitationCount" : 0, "scopusCitationCount" : 0, "independentCitationCount" : 0, "unhandledCitationCount" : 0, "citingPubCount" : 0, "independentCitingPubCount" : 0, "unhandledCitingPubCount" : 0, "citedPubCount" : 4, "citedCount" : 4, "referenceList" : "Colwell, J.A., New concepts about the pathogenesis of atherosclerosis in diabetes mellitus (1988) The Diabetic Foot, pp. 51-70. , Mosby-Year Book, St. Louis, M.E. Levin, L.W. O'Neal (Eds.); \n\nColwell, J.A., Peripheral vascular disease in diabetes mellitus (1986) Clinical Diabetes Mellitus, pp. 357-375. , Thieme Medical Publishers, New York, J. Davidson (Ed.); \n\nColwell, J.A., Winocour, P.D., Lopes-Virella, M.F., Platelet function and platelet interactions in atherosclerosis and diabetes mellitus (1989) Diabetes Mellitus: Theory and Practice, pp. 249-256. , Elsevier, New York, H. Rifkin, D. Porte (Eds.); \n\nLevin, M.E., Powers, M.A., Hypertension and diabetes: Then and now (1990) Diabetes Spectrum, 3, p. 274; \n\nDavis, N.S., Diabetic gangrene (1898) JAMA, 31, pp. 103-105; \n\nLawson, R.A., Amputations through the ages (1973) Aust N Z J Med, 42, pp. 221-230; \n\nWheelock, F.C., Marble, A., Surgery and diabetes (1971) Joslin's Diabetes Mellitus, pp. 599-620. , Lea & Febiger, Philadelphia, A. Marble, P. White, R.F. Bradley (Eds.); \n\nBell, E.T., Incidence of gangrene of the extremities in nondiabetic and diabetic persons (1960) Arch Pathol Lab Med, 49, pp. 469-473; \n\nBeach, K.W., The correlation of arteriosclerosis obliterans with lipoproteins in insulin-dependent and noninsulin-dependent diabetes (1979) Diabetes, 28, pp. 836-840; \n\nEpstein, F.H., Epidemiological studies of cardiovascular diseases in a total community: Tecumseh, Michigan (1965) Ann Intern Med, 62, pp. 1170-1187; \n\nJanka, H.U., Standl, E., Mehnert, H., Peripheral vascular disease in diabetes mellitus and its relation to cardiovascular risk factors: Screening with the Doppler ultrasonic technique (1980) Diabetes Care, 3, pp. 207-213; \n\nMelton, L.J., Incidence and prevalence of clinical peripheral vascular disease in a population-based cohort of 56 diabetic patients (1980) Diabetes Care, 3, pp. 650-654; \n\nOsmundson, P.J., Course of peripheral occlusive arterial disease in diabetes (1990) Diabetes Care, 2, pp. 143-152; \n\nPalumbo, P.J., Progression of peripheral occlusive arterial disease in diabetes mellitus: What factors are predictive (1991) Arch Intern Med, 151, pp. 717-721; \n\nUusitupa, M.I.J., 5-year incidence of atherosclerotic vascular disease in relation of general risk factors, insulin level, and abnormalities in lipoprotein composition in non-insulin-dependent diabetic and nondiabetic subjects (1990) Circulation, 82, pp. 27-36; \n\nGarcia, M.L., Morbidity and mortality in diabetics in Framingham population: Sixteen year follow-up study (1974) Diabetes, 23, pp. 105-111; \n\nBiesbroeck, R.C., Specific high affinity binding of HDL to cultured human skin fibroblasts and arterial smooth muscle cells (1983) J Clin Invest, 71, p. 525; \n\nDucimetier, P., Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population (1980) Diabetologia, 19, pp. 205-210; \n\nFontbonne, A.M., Insulin and cardiovascular disease: Paris prospective study (1991) Diabetes Care, 6, pp. 461-469; \n\nPyorala, K., Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: Results from two population studies in Finland (1979) Diabetes Care, 2, pp. 131-141; \n\nWelborne, T.A., Wearne, K., Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations (1979) Diabetes Care, 2, pp. 154-160; \n\nStandl, E., Janka, H.V., High serum insulin concentrations in relation to other cardiovascular risk factors in macrovascular disease of type 2 diabetes (1985) Horm Metab Res, 17 (SUPPL.), pp. 46-51; \n\nWorkshop on insulin and atherogenesis (1985) Metabolism, 12 (SUPPL. 1), pp. 1-91; \n\nStolar, M.W., Atherosclerosis in diabetes: The role of hyperinsulinemia (1988) Metabolism, 2 (SUPPL. 1), pp. 1-9; \n\nStout, R.W., Insulin and atheroma: An update (1987) Lancet, 1, p. 1077; \n\nBerliner, J.A., Atherosclerosis: Basic mechanisms: Oxidation, inflammation and genetics (1995) Circulation, 91, pp. 2488-2496; \n\nSchwenke, D.C., Carew, T.E., Initiation of atherosclerotic lesions in cholesterol-fed rabbits: II. Selective retention of LDL vs selective increases in LDL permeability in susceptible sites of arteries (1989) Arteriosclerosis, 9, pp. 908-918; \n\nFrank, F.S., Fogelman, A.M., Ultrastructure of the intima in WHHL and cholesterol-fed rabbit aortas prepared by ultra-rapid freezing and freeze-etching (1989) J Lipid Res, 30, pp. 967-978; \n\nNievelstein, P.F.E.M., Lipid accumulation in rabbit aortic intima 2 hours after bolus infusion of LDL: A deep-etch and immunolocalization study of rapidly frozen tissue (1991) Arterioscler Thromb, 11, pp. 1795-1805; \n\nNavab, M., Monocyte transmigration induced by modification of low density lipoprotein in co-cultures of human aortic wall cells is due to induction of monocyte chemotactic protein 1 synthesis and is abolished by high density lipoprotein (1991) J Clin Invest, 88, pp. 2039-2046; \n\nRajavashisth, T.B., Induction of endothelial cell expression of granulocyte and macrophage colony-stimulating factors by modified low density lipoproteins (1990) Nature, 344, pp. 254-257; \n\nSchwartz, D., The role of a gro homologue in monocyte adhesion to endothelium (1994) J Clin Invest, 94, pp. 1968-1973; \n\nHenriksen, T., Evensen, S.A., Carlander, B., Injury to human endothelial cells in culture induced by LDL (1979) Scand J Clin Lab Invest, 39, pp. 361-364; \n\nHessler, J.R., Robertson, A.L., Chisolm, G.M., LDL-induced cytotoxicity and its inhibition by HDL in human vascular smooth muscle and endothelial cells in culture (1979) Atherosclerosis, 32, pp. 213-218; \n\nFogelman, A.M., Malondialdehyde alteration of LDL leads to cholesterol ester accumulation in human monocytes/macrophages (1980) Proc Natl Acad Sci U S A, 77, pp. 2214-2218; \n\nHoff, H.F., Modification of LDL with 4-hydroxynonenal induces uptake by macrophages (1989) Arteriosclerosis, 9, pp. 538-549; \n\nJames, R.W., Pometta, D., Differences in lipoprotein subfraction composition and distribution between type I diabetic men and control subjects (1990) Diabetes, 39, pp. 1158-1164; \n\nJames, R.W., Pometta, D., The distribution profiles of very low and low density lipoproteins in poorly controlled male, type 2 (non-insulin-dependent) diabetic patients (1991) Diabetologia, 34, pp. 246-252; \n\nBucala, R., Vlassara, H., Advanced glycosylation end products in diabetic renal and vascular disease (1995) Am J Kidney Dis, 26, pp. 875-888; \n\nBrownlee, M., Vlassara, H., Cerami, A., Nonenzymatic glycosylation products on collagen covalently trap low-density lipoprotein (1985) Diabetes, 34, pp. 938-941; \n\nBrownlee, M., Pongor, S., Cerami, A., Covalent attachment of soluble proteins by non-enzymatically glycosylated collagen: Role in the in situ formation of immune complexes (1983) J Exp Med, 158, pp. 1739-1744; \n\nEsposito, C., Endothelial receptor-mediated binding of glucose-modified albumin is associated with increased monolayer permeability and modulation of cell surface coagulant properties (1989) J Exp Med, 170, pp. 1387-1407; \n\nDoi, T., Receptor-specific increase in extracellular matrix production in mouse mesangial cells by advanced glycosylation end products is mediated via platelet-derived growth factor (1992) Proc Natl Acad Sci U S A, 89, pp. 2873-2877; \n\nVlassara, H., Cachectin/TNF and IL-1 induced by glucose-modified proteins: Role in normal tissue remodeling (1988) Science, 240, pp. 1546-1548; \n\nBucala, R., Tracey, K.J., Cerami, A., Advanced glycosylation products quench nitric oxide and mediate defective endothelium-dependent vasodilatation in experimental diabetes (1991) J Clin Invest, 87, pp. 432-438; \n\nVlassara, H., Advanced glycation endproducts promote adhesion molecule (VCAM-1, ICAM-1) expression and atheroma formation in normal rabbits (1995) Mol Med, 1, pp. 447-456; \n\nVirella, G., Pro-atherogenic and pro-inflammatory properties of immune complexes prepared with purified human oxLDL antibodies and human oxLDL (2002) Clin Immunol, 105, pp. 81-92; \n\nVirella, G., Activation of human monocyte-derived macrophages by immune complexes containing low density lipoprotein (1995) Clin Immunol Immunopathol, 75, pp. 179-189; \n\nBeekhuizen, H., van Furth, R., Monocyte adherence to human vascular endothelium (1993) Leukoc Biol, 54, pp. 363-378; \n\nPohlman, T., An endothelial cell surface factor(s) induced in vitro by lipopolysaccharide, interleukin-1 and tumor necrosis factor increases neutrophil adherence by a CDw18-dependent mechanism (1986) J Immunol, 136, pp. 4548-4553; \n\nDavies, M.J., The expression of the adhesion molecules ICAM-1, VCAM-1, PECAM, and E-selectin in human atherosclerosis (1993) J Pathol, 171, p. 223; \n\nBevilacqua, M.P., Interleukin-1 induces biosynthesis and cell surface expression of procoagulant activity in human vascular endothelial cells (1984) J Exp Med, 160, pp. 618-622; \n\nBreviario, F., IL-induced adhesion of polymorphonuclear leukocytes to cultured human endothelial cells: Role of platelet-activating factor (1988) J Immunol, 141, pp. 3391-3397; \n\nMartin, S., IL-1 and INF- increase vascular permeability (1988) Immunology, 64, pp. 301-305; \n\nWarner, S.J.C., Auger, K.R., Libby, P., Interleukin-1 induces interleukin-1: II. Recombinant human interleukin-1 induces interleukin-1 production by adult human vascular endothelial cells (1987) J Immunol, 139, pp. 1911-1917; \n\nRaines, E.W., Dower, S.K., Ross, R., Interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA (1989) Science, 243, pp. 393-396; \n\nHansson, G.K., Immune mechanisms in atherosclerosis (1989) Arteriosclerosis, 9, pp. 567-578; \n\nNawroth, P.P., Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin-1 (1986) J Exp Med, 165, pp. 1363-1375; \n\nStevenson, H.C., Analysis of human blood monocyte activation at the level of gene expression (1985) J Exp Med, 161, pp. 503-513; \n\nNathan, C.F., Murray, H.W., Cohn, Z.A., The macrophage as an effector cell (1980) N Engl J Med, 303, pp. 622-626; \n\nRoss, R., Localization of PDGF-B protein in macrophages in all phases of atherogenesis (1990) Science, 248, pp. 1009-1012; \n\nAssoian, R.K., Expression and secretion of type beta transforming growth factor by activated human macrophages (1987) Proc Natl Acad Sci U S A, 84, pp. 6020-6024; \n\nFerreri, N.R., Howland, W.C., Spiegelberg, H.L., Release of leukotrienes C4 and B4 and prostaglandin E2 from human monocytes stimulated with aggregated IgG, IgA, and IgE (1986) J Immunol, 136, pp. 4188-4193; \n\nMusson, R.A., Shafran, H., Henson, P.M., Intracellular levels and stimulated release of lysosomal enzymes from human peripheral blood monocytes and monocyte-derived macrophages (1980) J Reticuloendothel Soc, 28, pp. 249-264; \n\nWerb, Z., Bonda, M.J., Jones, P.A., Degradation of connective tissue matrices by macrophages: I. Proteolysis of elastin, glycoproteins, and collagens by proteinases isolated from macrophages (1980) J Exp Med, 152, pp. 1340-1357; \n\nNakagawara, A., Nathan, C.F., Cohn, Z.A., Hydrogen peroxide metabolism in human monocytes during differentiation in vitro (1981) J Clin Invest, 68, pp. 1243-1252; \n\nMarx, N., Effect of rosiglitazone treatment on soluble CD40L in patients with type 2 diabetes and coronary heart disease (2003) Circulation, 107, pp. 1954-1957; \n\nGriffith, R.L., LDL metabolism by macrophages activated with LDL immune complexes: A possible mechanism of foam cell formation (1988) J Exp Med, 168, pp. 1041-1059; \n\nGisinger, C., Virella, G.T., Lopes-Virella, M.F., Erythrocyte-bound low density lipoprotein (LDL) immune complexes lead to cholesteryl ester accumulation in human monocyte derived macrophages (1991) Clin Immunol Immunopathol, 59, pp. 37-52; \n\nLopes-Virella, M.F., Enhanced uptake and impaired intracellular metabolism of LDL complexed with anti-LDL antibodies (1991) Arterioscler Thromb, 11, pp. 1356-1367; \n\nLopes-Virella, M.F., The uptake of LDL-IC by human macrophages: Predominant involvement of the FcgRI (1997) Atherosclerosis, 135, pp. 161-170; \n\nHuang, Y., Ghosh, M., Lopes-Virella, M.F., Transcriptional and posttranscriptional regulation of LDL receptor gene expression in PMA-treated THP-1 cells by LDL-IC (1997) J Lipid Res, 38, pp. 110-120; \n\nSalonen, J.T., Is there a continuing need for longitudinal epidemiologic research: The Kuopio ischaemic heart disease risk factor study (1988) Ann Clin Res, 20, pp. 46-50; \n\nPalinski, W., Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein (1990) Arteriosclerosis, 10, pp. 325-335; \n\nMaggi, E., LDL oxidation in patients with severe carotid atherosclerosis: A study of in vitro and in vivo oxidation markers (1994) Arterioscler Thromb, 14, pp. 1892-1899; \n\nSalonen, J.T., Autoantibody against oxidized LDL and progression of carotid atherosclerosis (1992) Lancet, 339, pp. 883-887; \n\nLehtimaki, T., Autoantibodies against oxidized low density lipoprotein in patients with angiographically verified coronary artery disease (1999) Arterioscl Thromb Vasc Biol, 19, pp. 23-27; \n\nErkkilä, A.T., Autoantibodies against oxidized low-density lipoprotein and cardiolipin in patients with coronary heart disease (2000) Arterioscl Thromb Vasc Biol, 20, pp. 204-209; \n\nBellomo, G., Autoantibodies against oxidatively modified low-density lipoproteins in NIDDM (1995) Diabetes, 44, pp. 60-66; \n\nPalinski, W., Immunological evidence for the presence of AGE in atherosclerotic lesions of euglycemic rabbits (1995) Arterioscler Thromb Vasc Biol, 15, pp. 571-582; \n\nTurk, Z., Detection of autoantibodies against advanced glycation endproducts and AGE-immune complexes in serum of patients with diabetes mellitus (2001) Clin Chim Acta, 303, pp. 105-115; \n\nVirella, G., Anti-oxidized low-density lipoprotein antibodies in patients with coronary heart disease and normal healthy volunteers (1993) Int J Clin Lab Res, 23, pp. 95-101; \n\nBoullier, A., Detection of autoantibodies against oxidized low-density lipoproteins and of IgG-bound low density lipoproteins in patients with coronary artery disease (1995) Clin Chim Acta, 238, pp. 1-10; \n\nUusitupa, M.I.J., Autoantibodies against oxidized LDL do not predict atherosclerosis vascular disease in non-insulin-dependent diabetes mellitus (1996) Arterioscl Thromb Vasc Biol, 16, pp. 1236-1242; \n\nvan de Vijver, L.P., Autoantibodies against MDA-LDL in subjects with severe and minor atherosclerosis and healthy population controls (1996) Atherosclerosis, 122, pp. 245-253; \n\nLeinonen, J.S., The level of autoantibodies against oxidized LDL is not associated with the presence of coronary heart disease or diabetic kidney disease in patients with non-insulin-dependent diabetes mellitus (1998) Free Radic Res, 29, pp. 137-141; \n\nFesta, A., Autoantibodies to oxidised low density lipoproteins in IDDM are inversely related to metabolic control and microvascular complications (1998) Diabetologia, 41, pp. 350-356; \n\nWu, R., Autoantibodies to OxLDL are decreased in individuals with borderline hypertension (1999) Hypertension, 33, pp. 53-59; \n\nLopes-Virella, M.F., Antibodies to oxidized LDL and LDL-containing immune complexes as risk factors for coronary artery disease in diabetes mellitus (1999) Clin Immunol, 90, pp. 165-172; \n\nHulthe, J., Antibodies to oxidized LDL in relation to carotid atherosclerosis, cell adhesion molecules, and phospholipase A(2) (2001) Arterioscler Thromb Vasc Biol, 21, pp. 269-274; \n\nShaw, P.X., Natural antibodies with the T15 idiotype may act in atherosclerosis, apoptotic clearance, and protective immunity (2000) J Clin Invest, 105, pp. 1731-1740; \n\nWu, R., Lefvert, A.K., Autoantibodies against oxidized low density lipoproteins (oxLDL): Characterization of antibody isotype, subclass, affinity and effect on the macrophage uptake of oxLDL (1995) Clin Exp Immunol, 102, pp. 174-180; \n\nPalinski, W., Witztum, J.L., Immune responses to oxidative neoepitopes on LDL and phospholipids modulate the development of atherosclerosis (2000) J Intern Med, 247, pp. 371-380; \n\nHansson, G.K., Vaccination against atherosclerosis: science or fiction? (2002) Circulation, 106, pp. 1599-1601; \n\nVirella, G., Immunochemical characterization of purified human oxidized low-density lipoprotein antibodies (2000) Clin Immunol, 95, pp. 135-144; \n\nVirella, G., Autoimmune response to advanced glycosylation end-products of human low density lipoprotein (2003) J Lipid Research, 443, pp. 487-493; \n\nVirella, G., Tsokos, G., Immune complex diseases (2002) Medical Immunology, pp. 453-471. , Marcel Dekker, New York, G. Virella (Ed.); \n\nHulthe, J., Bokemark, L., Fagerberg, B., Antibodies to oxidized LDL in relation to intima-media thickness in carotid and femoral arteries in 58-year-old subjectively clinically healthy men (2001) Arterioscler Thromb Vasc Biol, 21, pp. 101-107; \n\nFagerberg, B., Bokemark, L., Hulthe, J., The metabolic syndrome, smoking, and antibodies to oxidized LDL in 58-year-old clinically healthy men (2001) Nutr Metab Cardiovasc Dis, 11, pp. 227-235; \n\nVirella, G., Lopes-Virella, M.F., Lipoprotein autoantibodies: Measurement and significance (2003) Clin Diag Lab Immunol, 10, pp. 499-505; \n\nSzondy, E., Occurrence of anti-low density lipoprotein antibodies and circulating immune complexes in aged subjects (1985) Mech Ageing Dev, 29, pp. 117-123; \n\nTertov, V.V., Low density lipoprotein-containing circulating immune complexes and coronary atherosclerosis (1990) Exp Mol Pathol, 52, pp. 300-308; \n\nAtchley, D., Oxidized LDL-anti-oxidized LDL immune complexes and diabetic nephropathy (2002) Diabetologia, 45, pp. 1562-1571; \n\nFalk, E., Why do plaques rupture (1992) Circulation, 86 (SUPPL. III), pp. 3-30. , 3-42; \n\nGiroud, D., Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography (1992) Am J Cardiol, 69, pp. 729-732; \n\nLittle, W.C., Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-moderate coronary artery disease (1988) Circulation, 78, pp. 1157-1166; \n\nLibby, P., Molecular bases of the acute coronary syndromes (1995) Circulation, 91, pp. 2844-2850; \n\nAmento, E.P., Cytokine positively and negatively regulate interstitial collagen gene expression in human vascular smooth muscle cells (1991) Arterioscler Thromb, 11, pp. 1223-1230; \n\nHansson, G.K., Holm, J., Jonasson, L., Detection of activated T lymphocytes in the human atherosclerotic plaques (1989) Am J Pathol, 135, pp. 169-175; \n\nvan der Wal, A.C., Site of intimal rupture or erosion of thrombosed coronary atherosclerotic plaques is characterized by an inflammatory process irrespective of the dominant plaque morphology (1994) Circulation, 89, pp. 36-44; \n\nFuster, V., Lewis, A., Conner Memorial Lecture. Mechanisms leading to myocardial infarction: Insights from studies of vascular biology (1994) Circulation, 90, pp. 2126-2146; \n\nMorton, L.F., Barnes, M., Collagen polymorphism in the normal and diseased blood vessel wall. Investigation of collagens types I, III and V (1982) Atherosclerosis, 42, pp. 41-51; \n\nHanson, A.N., Bentley, J.P., Quantitation of type I to type III collagen ratios in small samples of human tendon, blood vessels, and atherosclerotic plaques (1983) Anal Biochem, 130, pp. 32-40; \n\nMatrisian, L.M., The matrix-degrading metalloproteinases (1992) BioEssays, 14, pp. 455-463; \n\nSukhova, G., Colocalization of the interstitial collagenase MMP-1 and MMP-13 with sites of cleaved collagen indicates their role in plaque destabilization (1998) Circulation, 98 (SUPPL.), pp. 1-48; \n\nHuang, Y., Mironova, M., Lopes-Virella, M.F., Oxidized LDL stimulates matrix metalloproteinase-1 expression in human vascular endothelial cells (1999) Arterioscler Thromb Vasc Biol, 19, pp. 2640-2647; \n\nHuang, Y., Fc-gamma receptor cross-linking by immune complexes induces matrix metalloproteinase-1 in U937 cells via mitogen-activated protein kinase (2000) Arterioscler Thromb Vasc Biol, 20, pp. 2533-2538; \n\nHuang, Y., Oxidized LDL differentially regulates MMP-1 and TIMP-1 expression in vascular endothelial cells (2001) Atherosclerosis, 156, pp. 119-125; \n\nMarx, N., Antidiabetic PPAR-activator rosiglitazone reduces MMP-9 serum levels in type 2 diabetic patients with coronary artery disease (2003) Arterioscler Thromb Vasc Biol, 23, pp. 283-288; \n\nUemura, S., Diabetes mellitus enhances vascular matrix metalloproteinase activity: Role of oxidative stress (2001) Circ Res, 88, pp. 1291-1298; \n\nShi, G.P., Molecular cloning and expression of human alveolar macrophage cathepsin S, an elastinolytic cysteine protease (1992) J Biol Chem, 267, pp. 7258-7262; \n\nKafienah, W., Human Cathepsin K cleaves native type I and II collagens at the N-terminal end of the triple helix (1998) Biochem J, 331, pp. 727-732; \n\nReddy, V.Y., Zhang, Q.Y., Weiss, S.J., Pericellular mobilization of the tissue-destructive cysteine proteinases, cathepins B, L, and S, by human monocyte-derived macrophages (1995) Proc Natl Acad Sci U S A, 92, pp. 3849-3853; \n\nSukhova, G.K., Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells (1998) J Clin Invest, 102, pp. 576-583; \n\nJormsjo, S., Differential expression of cysteine and aspartic proteases during progression of atherosclerosis in apolipoprotein E-deficient mice (2002) Am J Pathol, 161, pp. 939-945; \n\nChen, J., In vivo imaging of proteolytic activity in atherosclerosis (2002) Circulation, 105, pp. 2766-2771; \n\nGacko, M., Glowinski, S., Cathepsin D and cathepsin L activities in aortic aneurysm wall and parietal thrombus (1998) Clin Chem Lab Med, 36, pp. 449-452; \n\nShi, G.P., Cystatin C deficiency in human atherosclerosis and aortic aneurysms (1999) J Clin Invest, 104, pp. 1191-1197; \n\nSchaub, F.J., Fas/FADD-mediated activation of a specific program of inflammatory gene expression in vascular smooth muscle cells (2000) Nature Med, 6, pp. 790-796; \n\nTedgui, A., Mallat, Z., Apoptosis as a determinant of atherothrombosis (2001) Thromb Haemost, 86, pp. 420-426; \n\nMoons, A.H., Levi, M., Peters, R.J., Tissue factor and coronary heart disease (2002) Cardiovasc Res, 53, pp. 313-325; \n\nFurchgott, R.F., Zawadzki, J.V., The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine (1980) Nature, 299, pp. 373-376; \n\nIgnarro, L.J., Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide (1987) Proc Natl Acad Sci U S A, 84, pp. 9265-9269; \n\nPalmer, R.M.J., Ferrige, A.F., Moncada, S., Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor (1987) Nature, 327, pp. 524-526; \n\nMoncada, S., Palmer, R.M.J., Higgs, E.A., Nitric oxide: Physiology, pathophysiology, and pharmacology (1991) Pharmacol Rev, 43, pp. 109-142; \n\nPalmer, R.M.J., Ashton, D.S., Moncada, S., Vascular endothelial cells synthesize nitric oxide from L-arginine (1988) Nature, 333, pp. 664-666; \n\nNaseem, K.M., The role of nitric oxide in cardiovascular diseases (2005) Mol Aspects Med, 26, pp. 33-65; \n\nLlorens, S., Nava, E., Cardiovascular diseases and the nitric oxide pathway (2003) Curr Vasc Pharmacol, 1, pp. 335-346; \n\nJi, Y., Inhibition of endothelial nitric oxide generation by low-density lipoprotein is partially prevented by L-arginine and L-ascorbate (2004) Atherosclerosis, 176, pp. 345-353; \n\nGoulter, A.B., Chylomicron-remnant-like particles inhibit the basal nitric oxide pathway in porcine coronary artery and aortic endothelial cells (2003) Clin Sci (Lond), 105, pp. 363-371; \n\nTakahashi, M., Very low density lipoprotein enhances inducible nitric oxide synthase expression in cytokine-stimulated vascular smooth muscle cells (2002) Atherosclerosis, 162, pp. 307-313; \n\nMineo, C., High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAPkinases (2003) J Biol Chem, 278, pp. 9142-9149; \n\nYuhanna, I.S., High-density lipoprotein binding to scavenger receptor-BI activates endothelial nitric oxide synthase (2001) Nat Med, 7, pp. 853-857; \n\nSpieker, L.E., High-density lipoprotein restores endothelial function in hypercholesterolemic men (2002) Circulation, 105, pp. 1399-1402; \n\nBalletshofer, B.M., Intense cholesterol lowering therapy with HMG-CoA reductase inhibitor does not improve nitric oxide dependent endothelial function in type 2 diabetes: A multicenter, randomized, double-blind, three-arm, placebo-controlled clinical trial (2005) Exp Clin Endocr Diab, 113, pp. 324-330; \n\nCassone Faldetta, M., L-arginine infusion decreases plasma total homocysteine concentrations through increased nitric oxide production and decreased oxidative status in Type 2 diabetic patients (2002) Diabetologia, 45, pp. 1120-1127; \n\nAvogaro, A., L-arginine-nitric oxide kinetics in normal and type 2 diabetic subjects: A stable-labeled 15N arginine approach (2003) Diabetes, 52, pp. 795-802; \n\nvan Etten, R.W., Impaired NO-dependent vasodilation in patients with Type II (non-insulin-dependent) diabetes mellitus is restored by acute administration of folate (2002) Diabetologia, 45, pp. 1004-1010; \n\nAkbari, C.M., Endothelium-dependent vasodilatation is impaired in both microcirculation and macrocirculation during acute hyperglycemia (1998) J Vasc Surg, 28, pp. 687-694; \n\nWilliams, S.B., Acute hyperglycemia attenuates endothelium-dependent vasodilatation in humans in vivo (1998) Circulation, 97, pp. 1695-1701; \n\nTaubert, D., Acute effects of glucose and insulin on vascular endothelium (2004) Diabetologia, 47, pp. 2059-2071; \n\nMilsom, A.B., Abnormal metabolic fate of nitric oxide in type 1 diabetes mellitus (2002) Diabetologia, 45, pp. 1515-1522; \n\nJames, P.E., Vasorelaxation by red blood cells and impairment in diabetes: Reduced nitric oxide and oxygen delivery by glycated hemoglobin (2004) Circ Res, 94, pp. 976-983; \n\nCosby, K., Nitrite reduction to nitric oxide by deoxyhemoglobin vasodilates the human circulation (2003) Nat Med, 9, pp. 1498-1505; \n\nRogers, S.C., Detection of human red blood cell-bound nitric oxide (2005) J Biol Chem, 29, pp. 26720-26728; \n\nGladwin, M.T., Schechter, A.N., NO contest: Nitrite versus S-nitrosohemoglobin (2004) Circ Res, 94, pp. 851-855; \n\nRodriguez-Manas, L., Effect of glycaemic control on the vascular nitric oxide system in patients with type 1 diabetes (2003) J Hypertens, 21, pp. 1137-1143; \n\nHeitzer, T., Tetrahydrobiopterin improves endothelium-dependent vasodilation by increasing nitric oxide activity in patients with type II diabetes mellitus (2000) Diabetologia, 43, pp. 1435-1438; \n\nBagi, Z., Koller, A., Lack of nitric oxide mediation of flow-dependent arteriolar dilation in type 1 diabetes is restored by sepiapterin (2003) J Vasc Res, 40, pp. 47-57; \n\nWerner, E.R., Tetrahydrobiopterin and nitric oxide: Mechanistic and pharmacological aspects (2003) Exp Biol Med, 228, pp. 1291-1302; \n\nFarkas, K., Endothelial nitric oxide in diabetes mellitus: Too much or not enough? (2000) Diabetes Nutr Metab Clin Exper, 13, pp. 287-297; \n\nMaejima, K., Increased basal levels of plasma nitric oxide in type 2 diabetic subjects: Relationship to microvascular complications (2001) J Diabetes Complications, 15, pp. 135-143; \n\nOzden, S., Basal serum nitric oxide levels in patients with type 2 diabetes mellitus and different states of retinopathy (2003) Can J Ophthalmol, 38, pp. 393-396; \n\nPricci, F., Oxidative stress in diabetes-induced endothelial dysfunction involvement of nitric oxide and protein kinase C (2003) Free Radic Biol Med, 35, pp. 683-694; \n\nDu, Y., Diabetes-induced nitrative stress in the retina, and correction by aminoguanidine (2002) J Neurochem, 80, pp. 771-779; \n\nChiarelli, F., Increased circulating nitric oxide in young patients with type 1 diabetes and persistent microalbuminuria: Relation to glomerular hyperfiltration (2000) Diabetes, 49, pp. 1258-1263; \n\nApakkan Aksun, S., Serum and urinary nitric oxide in type 2 diabetes with or without microalbuminuria: Relation to glomerular hyperfiltration (2003) J Diabetes Complications, 17, pp. 343-348; \n\nHiragushi, K., Nitric oxide system is involved in glomerular hyperfiltration in Japanese normo- and micro-albuminuric patients with type 2 diabetes (2001) Diabetes Res Clin Prac, 53, pp. 149-159; \n\nShankar, S.S., Steinberg, H.O., Obesity and endothelial dysfunction (2005) Semin Vasc Med, 5, pp. 56-64; \n\nPotenza, M.A., Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production (2005) Am J Physiol Heart C, 289, pp. H813-H822; \n\nFacchini, F.S., Blood pressure, sodium intake, insulin resistance, and urinary nitrate excretion (1999) Hypertension, 33, pp. 1012-1088; \n\nWilliams, I.L., Obesity, atherosclerosis and the vascular endothelium: Mechanisms of reduced nitric oxide bioavailability in obese humans (2002) Int J Obesity, 26, pp. 754-764; \n\nVincent, M.A., Montagnani, M., Quon, M.J., Molecular and physiologic actions of insulin related to production of nitric oxide in vascular endothelium (2003) Cur Diab Rep, 3, pp. 279-288; \n\nChien, W.Y., Increased plasma concentration of nitric oxide in type 2 diabetes but not in nondiabetic individuals with insulin resistance (2005) Diabetes Metab, 31, pp. 63-68; \n\nZavaroni, I., Plasma nitric oxide concentrations are elevated in insulin-resistant healthy subjects (2000) Metabolism, 49, pp. 959-961; \n\nColwell, J.A., New concepts about the pathogenesis of atherosclerosis in diabetes mellitus (1993) The Diabetic Foot, pp. 79-114. , Mosby Year Book, St. Louis, M.E. Levin, L.W. O'Neal, J.H. Bowker (Eds.); \n\nScotland, R.S., Investigation of vascular responses in endothelial nitric oxide synthase/cyclooxygenase-1 double-knockout mice: Key role for endothelium-derived hyperpolarizing factor in the regulation of blood pressure in vivo (2005) Circulation, 111, pp. 796-803; \n\nTriggle, C.R., Ding, H., Endothelium-derived hyperpolarizing factor: Is there a novel chemical mediator? (2002) Clin Experim Pharm Physiol, 29, pp. 153-160; \n\nBusse, R., EDHF: Bringing the concepts together (2002) Trends Pharm Sci, 23, pp. 374-380; \n\nCohen, R.A., The endothelium-derived hyperpolarizing factor puzzle: A mechanism without a mediator? (2005) Circulation, 111, pp. 724-727; \n\nColwell, J.A., Atherosclerosis and thrombosis in diabetes mellitus: New aspects of pathogenesis (2000) The Diabetic Foot, pp. 65-106. , Elsevier Health Sciences, St. Louis, J.H. Bowker, M.A. Pfeifer (Eds.); \n\nHashimoto, T., Lysophosphatidylcholine inhibits the expression of prostacyclin stimulating factor in cultured vascular smooth muscle cells (2002) J Diab Complications, 16, pp. 81-86; \n\nMatsumoto, K., Impaired endothelial dysfunction in diabetes mellitus rats was restored by oral administration of prostaglandin I2 analogue (2002) J Endocrinol, 175, pp. 217-223; \n\nYamashita, T., Beraprost sodium, prostacyclin analogue, attenuates glomerular hyperfiltration and glomerular macrophage infiltration by modulating ecNOS expression in diabetic rats (2002) Diabetes Res Clin Pract, 57, pp. 149-161; \n\nAso, Y., Changes in skin blood flow in type 2 diabetes induced by prostacyclin: Association with ankle brachial index and plasma thrombomodulin levels (2001) Metabolism, 50, pp. 568-572; \n\nOwada, A., Suda, S., Hata, T., Effect of long-term administration of prostaglandin I(2) in incipient diabetic nephropathy (2002) Nephron, 92, pp. 788-796; \n\nGoya, K., Effects of the prostaglandin I 2 analogue, beraprost sodium, on vascular cell adhesion molecule-1 expression in human vascular endothelial cells and circulating vascular cell adhesion molecule-1 level in patients with type 2 diabetes mellitus (2003) Metabolism, 52, pp. 192-198; \n\nFu, J.Y., The induction and suppression of prostaglandin H2 synthase (cyclooxygenase) in human monocytes (1990) J Biol Chem, 265, pp. 16737-16740; \n\nKonieczkowski, M., Skrinska, V.A., Increased synthesis of thromboxane A 2 and expression of procoagulant activity by monocytes in response to arachidonic acid in diabetes mellitus (2001) Prostag Leukotr Essent Fatty Acids, 65, pp. 133-138; \n\nFujiwara, T., Ohsawa, T., Takahashi, S., Troglitazone, a new antidiabetic agent possessing radical scavenging ability, improved decreased skin blood flow in diabetic rats (1998) Life Sci, 63, pp. 2039-2047; \n\nHishinuma, T., Yamazaki, Y., Mizugaki, M., Troglitazone has a reducing effect on thromboxane production (2000) Prostag Lipid Mediat, 62, pp. 135-143; \n\nYanagisawa, M., A novel potent vasoconstrictor peptide produced by vascular endothelial cells (1988) Nature, 332, pp. 411-415; \n\nMarkewitz, B.A., Michael, J.R., Kohan, D.E., Endothelin-1 inhibits the expression of inducible nitric oxide synthase (1997) Am J Physiol, 272, pp. L1078-L1083; \n\nKhan, A.S., Chakrabarti, S., Endothelins in chronic diabetic complications (2003) Can J Physiol Pharmacol, 81, pp. 622-634; \n\nMather, K.J., Interactions between endothelin and nitric oxide in the regulation of vascular tone in obesity and diabetes (2004) Diabetes, 53, pp. 2060-2066; \n\nLam, H.-C., Role of endothelin in diabetic retinopathy (2003) Curr Vasc Pharm, 1, pp. 243-250; \n\nSchram, M.T., Stehouwer, C.D.A., Endothelial dysfunction, cellular adhesion molecules and the metabolic syndrome (2005) Horm Metab Res, 37 (SUPPL. 1), pp. 49-55; \n\nBlankenberg, S., Barbaux, S., Tiret, L., Adhesion molecules and atherosclerosis (2003) Atherosclerosis, 170, pp. 191-203; \n\nLeeuwenberg, J.F., E-selectin and intracellular adhesion molecule-1 are released by activated human endothelial cells in vitro (1992) Immunology, 77, pp. 543-549; \n\nSchmidt, A.M., Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VACM-1) in cultured human endothelial cells and in mice: A potential mechanism of the accelerated vasculopathy of diabetes (1995) J Clin Invest, 96, pp. 1395-1403; \n\nSchram, M.T., The EURODIAB Prospective Complications Study Group: Vascular risk factors and markers of endothelial function as determinants of inflammatory markers in type 1 diabetes (2003) Diab Care, 26, pp. 2165-2173; \n\nStehouwer, D.C., Increased urinary albumin excretion, endothelial dysfunction, and chronic low-grade inflammation in type 2 diabetes: Progressive, interrelated, and independently associated with risk of death (2002) Diabetes, 51, pp. 1157-1165; \n\nBerenson, G.S., Association between multiple cardiovascular risk factors and atherosclerosis in children and young adults: The Bogalusa Heart Study (1998) N Engl J Med, 338, pp. 1650-1656; \n\nGlowinska, B., Soluble adhesion molecules (sICAM-1, sVCAM-1) and selectins (sE selectin, sP selectin, sL selectin) levels in children and adolescents with obesity, hypertension, and diabetes (2005) Metab Clin Exper, 54, pp. 1020-1026; \n\nKowalska, I., Circulating E-selectin, vascular cell adhesion molecule-1, and intercellular adhesion molecule-1 in men with coronary artery disease assessed by angiography and disturbances of carbohydrate metabolism (2002) Metabolism, 51, pp. 733-736; \n\nSchram, M.T., Stehouwer, C.D.A., Endothelial dysfunction, cellular adhesion molecules and the metabolic syndrome (2005) Horm Metab Res, 37 (SUPPL. 1), pp. 49-55; \n\nLyons, T.J., Jenkins, A.J., Glycation, oxidation and lipoxidation in the development of the complications of diabetes mellitus: A \"carbonyl stress\" hypothesis (1997) Diabetes Rev, 5, pp. 365-391; \n\nLyons, T.J., Glycation, carbonyl stress, EAGLEs, and the vascular complications of diabetes (2002) Sem Vasc Med, 2, pp. 175-189; \n\nHamlin, C.R., Kohn, R.R., Evidence for progressive, age-related structural changes in post-mature human collagen (1971) Biochim Biophys Acta, 236, pp. 458-467; \n\nLyons, T.J., Decrease in skin collagen glycosylation with improved glycemic control in patients with insulin-dependent diabetes mellitus (1991) J Clin Invest, 87, pp. 1910-1915; \n\nMonnier, V.M., Relations between complications to type I diabetes mellitus and collagen-linked fluorescence (1986) N Engl J Med, 314, pp. 403-408; \n\nOxlund, H., Increased aortic stiffness in patients with type 1 (insulin-dependent) diabetes mellitus (1989) Diabetologia, 32, pp. 748-752; \n\nHicks, M., Increase in crosslinking of nonenzymatically glycosylated collagen induced by products of lipid peroxidation (1989) Arch Biochem Biophys, 268, pp. 249-254; \n\nRequena, J.R., Lipoxidation products as biomarkers of oxidative damage to proteins during lipid peroxidation reactions (1996) Nephrol Dial Transplant, 11 (SUPPL. 5), pp. 48-53; \n\nSong, W., Effect of native LDL and modified LDL on mRNA expression of genes in human retinal pericytes (2005) Invest Ophthalmol Vis Sci, 46, pp. 2974-2982; \n\nKirstein, M., Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: Role in vascular disease of diabetes and aging (1990) Proc Natl Acad Sci U S A, 87, pp. 9010-9014; \n\nVlassara, H., Brownlee, M., Cerami, A., Novel macrophage receptor for glucose-modified proteins is distinct from previously described scavenger receptors (1986) J Exp Med, 164, pp. 1301-1309; \n\nVlassara, H., Advanced glycosylation end products on erythrocyte cell surface induce receptor-mediated phagocytosis by macrophages: A model for turnover of aging cells (1987) J Exp Med, 166, pp. 539-549; \n\nHudson, B.I., Diabetic vascular disease: It's all the RAGE (2005) Antioxid Redox Signal, 7, pp. 1588-1600; \n\nValencia, J.V., Divergent pathways of gene expression are activated by the RAGE ligands S100b and AGE-BSA (2004) Diabetes, 53, pp. 743-751; \n\nIchikawa, K., Advanced glycosylation end products induced tissue factor expression in human monocytes (1996) Diabetes, 45 (SUPPL. 2), pp. 128A; \n\nImani, F., Advanced glycosylation endproduct-specific receptors on human and rat T-lymphocytes mediate synthesis of interferon gamma: Role in tissue remodeling (1993) J Exp Med, 178, pp. 2165-2172; \n\nThrockmorton, D.C., PDGF and TGF-beta mediate collagen production by mesangial cells exposed to advanced glycosylation end products (1995) Kidney Int, 48, pp. 111-117; \n\nChibber, R., Molinatti, P.A., Kohner, E.M., Potential role of glucose-mediated proteins in the pathogenesis of diabetic retinopathy (1996) Diabetes, 45 (SUPPL. 2), pp. 15A; \n\nStitt, A.W., Intracellular advanced glycation endproducts (AGEs) co-localize with AGE-receptors in the retinal vasculature of diabetic and AGE-infused rats (1996) Diabetes, 45 (SUPPL. 2), pp. 15A; \n\nYamagishi, S., Receptor-mediated toxicity to pericytes of advanced glycosylation end products: A possible mechanism of pericyte loss in diabetic microangiopathy (1995) Biochem Biophys Res Commun, 213, pp. 681-687; \n\nHori, O., Advanced glycation endproducts interacting with their endothelial receptor induce expression of vascular cell adhesion molecule-1 (VCAM-1) in cultured human endothelial cells and in mice: A potential mechanism for the accelerated vasculopathy of diabetes (1995) J Clin Invest, 96, pp. 1395-1403; \n\nHudson, B.I., Schmidt, A.M., RAGE: A novel target for drug intervention in diabetic vascular disease (2004) Pharm Res, 7, pp. 1079-1086; \n\nWautier, J.L., Receptor-mediated endothelial cell dysfunction in diabetic vasculopathy: Soluble receptor for advanced glycation end products blocks hyperpermeability in diabetic rats (1996) J Clin Invest, 97, pp. 238-243; \n\nMakita, Z., Advanced glycosylation end products in patients with diabetic nephropathy (1991) N Engl J Med, 325, pp. 836-842; \n\nMcCance, D.R., Maillard reaction products and their relation to complications in insulin dependent diabetes mellitus (1993) J Clin Invest, 91, pp. 2470-2478; \n\nSell, D.R., Pentosidine formation in skin correlates with severity of complications in individuals with long-standing IDDM (1992) Diabetes, 41, pp. 1286-1292; \n\nVlassara, H., Advanced glycation end products induce glomerular sclerosis and albuminuria in normal rats (1994) Proc Natl Acad Sci U S A, 91, pp. 11704-11708; \n\nYang, C.W., Administration of AGEs in vivo induces genes implicated in diabetic glomerulosclerosis (1995) Kidney Int, 49, pp. S55-S58; \n\nAbel, M., Expression of receptors for advanced glycosylated end-products in renal disease (1995) Nephrol Dial Transplant, 10, pp. 1662-1667; \n\nBeisswenger, P.J., Susceptibility to diabetic nephropathy is related to dicarbonyl and oxidative stress (2005) Diabetes, 54, pp. 3274-3281; \n\nGenuth, S., Glycation and carboxymethyllysine levels in skin collagen predict the risk of future 10-year progression of diabetic retinopathy and nephropathy in the diabetes control and complications trial and epidemiology of diabetes interventions and complications participants with Type 1 diabetes (2005) Diabetes, 54, pp. 3103-3111; \n\nEffect of intensive therapy on the microvascular complications of type 1 diabetes nellitus (2002) JAMA, 287, pp. 2563-2569. , Writing Team for the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Research Group; \n\nReaven, P., Effects of oleate-rich and linoleate-rich diets on the susceptibility of low density lipoprotein to oxidative modification in mildly hypercholesterolemic subjects (1993) J Clin Invest, 91, pp. 668-676; \n\nColhoun, H.M., On behalf of the CARDS investigators. Rapid emergence of effect of atorvastatin on cardiovascular outcomes in the Collaborative Atorvastatin Diabetes Study (CARDS) (2005) Diabetologia, 48, pp. 2482-2485; \n\nFrei, B., England, L., Ames, B.N., Ascorbate is an outstanding antioxidant in human plasma (1989) Proc Natl Acad Sci U S A, 86, pp. 6377-6381; \n\nJennings, P.E., Vitamin C metabolites and microangiopathy in diabetes mellitus (1987) Diabetes Res, 6, pp. 151-154; \n\nKarpen, C.W., Production of 12 HETE and vitamin E status in platelets from type 1 human diabetic subjects (1985) Diabetes, 34, pp. 526-531; \n\nYoung, I.S., Torney, J.J., Trimble, E.R., The effect of ascorbate supplementation on oxidative stress in the streptozotocin diabetic rat (1992) Free Radic Biol Med, 13, pp. 41-46; \n\nBowry, V.W., Stocker, R., Vitamin E in human low-density lipoprotein: When and how this antioxidant becomes a pro-oxidant (1992) Biochem J, 288, pp. 341-344; \n\nParthasarathy, S., Probucol inhibits oxidative modification of low density lipoprotein (1986) J Clin Invest, 77, pp. 641-644; \n\nCarew, T.E., Schwenke, D.C., Steinberg, D., Antiatherogenic effect of probucol unrelated to its hypocholesterolemic effect: Evidence that antioxidants in vivo can selectively inhibit low density lipoprotein degradation in macrophage-rich fatty streaks and slow the progression of atherosclerosis in the Watanabe heritable hyperlipidemic rabbit (1987) Proc Natl Acad Sci U S A, 84, pp. 7725-7729; \n\nKita, T., Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia (1987) Proc Natl Acad Sci U S A, 84, pp. 5928-5931; \n\nKuzuya, M., Probucol prevents oxidative injury to endothelial cells (1991) J Lipid Res, 32, pp. 197-204; \n\nBjörkhem, I., The antioxidant butylated hydroxytoluene protects against atherosclerosis (1991) Arterioscler Thromb, 11, pp. 15-22; \n\nFreyschuss, A., Antioxidant treatment inhibits the development of intimal thickening after balloon injury of the aorta in hypercholesterolemic rabbits (1993) J Clin Invest, 91, pp. 1282-1288; \n\nThomas, S.R., Neuzil, J., Stocker, R., Cosupplementation with coenzyme Q prevents the prooxidant effect of α-tocopherol and increases the resistance of LDL to transition metal-dependent oxidation initiation (1996) Arterioscler Thromb Vasc Biol, 16, pp. 687-696; \n\nCoffey, M.D., In vitro cell injury by oxidized low density lipoprotein involves lipid hydroperoxide-induced formation of alkoxyl, lipid, and peroxyl radicals (1995) J Clin Invest, 96, pp. 1866-1873; \n\nBrownlee, M., Aminoguanidine prevents diabetes-induced arterial wall protein cross-linking (1986) Science, 232, pp. 1629-1632; \n\nBucala, R., Cerami, A., Phospholipids react with glucose to initiate advanced glycosylation and fatty acid oxidation: Inhibition of lipid advanced glycosylation and oxidation by aminoguanidine (1992) Diabetes, 41 (SUPPL. 1), pp. 23A; \n\nBucala, R., Inhibition of advanced glycosylation by aminoguanidine reduces plasma LDL levels in diabetes (1993) Clin Res, 41, pp. 183A; \n\nLyons, T.J., Li, W., Aminoguanidine and the cytotoxicity of modified LDL to retinal capillary endothelial cells (1994) Diabetes, 43 (SUPPL. 1), pp. 112A; \n\nHammes, H.P., Aminoguanidine inhibits the development of accelerated diabetic retinopathy in the spontaneous hypertensive rat (1994) Diabetologia, 37, pp. 32-35; \n\nHammes, H.P., Aminoguanidine treatment inhibits the development of experimental diabetic retinopathy (1991) Proc Natl Acad Sci U S A, 88, pp. 11555-11558; \n\nHammes, H.P., Secondary intervention with aminoguanidine retards the progression of diabetic retinopathy in the rat model (1995) Diabetologia, 38, pp. 656-660; \n\nEdelstein, D., Brownlee, M., Rapid communication: Aminoguanidine ameliorates albuminuria in diabetic hypertensive rats (1992) Diabetologia, 35, pp. 96-97; \n\nSoulis-Liparota, T., Retardation by aminoguanidine of development of albuminuria, mesangial expansion, and tissue fluorescence in streptozotocin-induced diabetic rat (1991) Diabetes, 40, pp. 1328-1334; \n\nCameron, N.E., Effects of aminoguanidine on peripheral nerve function and polyol pathway metabolites in streptozotocin diabetic rats (1992) Diabetologia, 35, pp. 946-950; \n\nKihara, M., Aminoguanidine effects on nerve blood flow, vascular permeability, electrophysiology, and oxygen free radicals (1991) Proc Natl Acad Sci U S A, 88, pp. 6107-6111; \n\nBolton, W.K., Randomized trial of an inhibitor of formation of advance glycation end products in diabetic Nephropathy (2004) Am J Nephrol, 24, pp. 32-40; \n\nBurch, R.M., N-(fluorenyl-9-methoxycarbonyl) amino acids, a class of anti-inflammatory agents with a different mechanism of action (1991) Proc Natl Acad Sci U S A, 88, pp. 355-359; \n\nNavab, M., A new anti-inflammatory compound, Leumedin, inhibits modification of low density lipoprotein and the resulting monocyte transmigration into the subendothelial space of cocultures of human aortic wall cells (1993) J Clin Invest, 91, pp. 1225-1230; \n\nStitt, A., Gardiner, T.A., The AGE inhibitor pyridoxamine inhibits development of retinopathy in experimental diabetes (2002) Diabetes, 51, pp. 2826-2832; \n\nDegenhardt, T.O., Pyridoxamine inhibits early renal disease and dyslipidemia in the streptozotocin-diabetic rat (2002) Kidney Int, 61, pp. 939-950; \n\nThallas-Bonke, V., Attenuation of extracellular matrix accumulation in diabetic nephropathy by the advanced glycation end product cross-link breaker ALT-711 via a protein kinase C-a-dependent pathway (2004) Diabetes, 53, pp. 2921-2930; \n\nLi, Y.M., Opsonization and removal of serum AGEs by coupling to lysozyme (1996) Diabetes, 45 (SUPPL. 2), pp. 239A; \n\nMitsuhashi, T., Depletion of reactive advanced glycation end-products (AGEs) from diabetic uremic sera by a lysozyme-linked matrix (1996) Diabetes, 45 (SUPPL. 2), pp. 47A; \n\nVasan, S., Design, synthesis, and pharmacological activity of a novel class of thiazolium-based compounds that cleave established AGE-derived protein crosslinks (1996) Diabetes, 45 (SUPPL. 2), pp. 28A; \n\nSteinberg, D., Antioxidants and atherosclerosis: A current assessment (1991) Circulation, 84, pp. 1420-1425; \n\nSmith, M.A., Advanced Maillard reaction end products, free radicals, and protein oxidation in Alzheimer's disease (1994) Ann N Y Acad Sci, 738, pp. 447-454; \n\nCalzada, C., 12(S)-hydroperoxyeicosatetraenoic acid increases arachidonic acid availability in collagen-primed platelets (2001) J Lipid Res, 42, pp. 1467-1473; \n\nPlasma fibrinogen level and the risk of major cardiovascular diseases and nonvascular mortality: An individual participant meta-analysis (2005) JAMA, 294, pp. 1799-1809. , Fibrinogen Studies Collaboration; \n\nKlein, R.L., Fibrinogen is a marker for nephropathy and peripheral vascular disease in type 1 diabetes: Studies of plasma fibrinogen and fibrinogen gene polymorphism in the DCCT/EDIC cohort (2003) Diabetes Care, 26, pp. 1439-1448; \n\nJones, R.L., Fibrinopeptide-A in diabetes mellitus (1985) Diabetes, 34, pp. 836-843; \n\nParamo, J.A., Prothrombin fragment 1+2 is associated with carotid intima-media thickness in subjects free of clinical cardiovascular disease (2004) Stroke, 35, pp. 1085-1089; \n\nCeriello, A., Hyperglycemia-induced thrombin formation in diabetes: The possible role of oxidative stress (1995) Diabetes, 44, pp. 924-928; \n\nCeriello, A., Fibrinogen plasma levels as a marker of thrombin activation in diabetes (1994) Diabetes, 43, pp. 430-432; \n\nVillanueva, G.B., Allen, N., Demonstration of altered antithrombin III activity due to nonenzymatic glycosylation at glucose concentration expected to be encountered in severely diabetic patients (1988) Diabetes, 37, pp. 1103-1107; \n\nPandolfi, A., Plasminogen activator inhibitor type 1 is increased in the arterial wall of type II diabetic subjects (2001) Arterioscler Thromb Vasc Biol, 21, pp. 1378-1382; \n\nColwell, J.A., Halushka, P.V., Platelet function in diabetes mellitus (1980) Br J Haematol, 44, pp. 521-526; \n\nOstermann, H., van de Loo, J., Factors of the haemostatic system in diabetic patients: A survey of controlled studies (1986) Haemostasis, 16, pp. 386-416; \n\nCollaborative overview of randomized trials of antiplatelet therapy: I. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients (1994) BMJ, 308, pp. 81-106. , Antiplatelet Trialists' Collaboration; \n\nCollaborative meta-analysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients (2002) BMJ, 324, pp. 71-86. , Antiplatelet Trialists' Collaboration; \n\nColwell, J.A., Aspirin therapy in diabetes (1997) Diabetes, 20, pp. 1767-1771; \n\nSanmuganathan, P.S., Aspirin for primary prevention of coronary heart disease: Safety and absolute benefit related to coronary risk derived from meta-analysis of randomized trials (2001) Heart, 85, pp. 265-271", "hasCitationDuplums" : false, "userChangeableUntil" : "2016-09-29T10:39:00.000+0000", "publishDate" : "2016-09-29T10:38:56.000+0000", "directInstitutesForSort" : "", "ownerAuthorCount" : 5, "ownerInstituteCount" : 42, "directInstituteCount" : 0, "authorCount" : 5, "contributorCount" : 0, "book" : { "otype" : "Book", "mtid" : 30200592, "link" : "/api/publication/30200592", "label" : "Bowker JH. Levin and O'Neal's: The Diabetic Foot. (2008) ISBN:9780323041454", "core" : false, "citation" : false, "publicationPending" : false, "type" : { "otype" : "PublicationType", "mtid" : 23, "link" : "/api/publicationtype/23", "label" : "Könyv", "code" : 23, "otypeName" : "Book", "listPosition" : 3, "published" : true, "oldId" : 23, "snippet" : true }, "category" : { "otype" : "Category", "mtid" : 1, "link" : "/api/category/1", "label" : "Tudományos", "published" : true, "oldId" : 1, "snippet" : true }, "languages" : [ { "otype" : "Language", "mtid" : 10002, "link" : "/api/language/10002", "label" : "Angol", "name" : "Angol", "nameEng" : "English", "published" : true, "oldId" : 2, "snippet" : true } ], "title" : "Levin and O'Neal's: The Diabetic Foot", "identifiers" : [ { "otype" : "PublicationIdentifier", "mtid" : 9487166, "link" : "/api/publicationidentifier/9487166", "label" : "ISBN: 9780323041454", "source" : { "otype" : "PlainSource", "mtid" : 122, "link" : "/api/publicationsource/122", "label" : "ISBN", "type" : { "otype" : "PublicationSourceType", "mtid" : 10002, "link" : "/api/publicationsourcetype/10002", "label" : "Egyéb", "mayHaveOa" : false, "published" : true, "snippet" : true }, "name" : "ISBN", "nameEng" : "ISBN", "linkPattern" : "https://www.worldcat.org/search?q=isbn%3A@@@", "publiclyVisible" : true, "published" : true, "oldId" : 122, "snippet" : true }, "idValue" : "9780323041454", "realUrl" : "https://www.worldcat.org/search?q=isbn%3A9780323041454", "published" : false, "snippet" : true } ], "publishedAt" : [ ], "publishedYear" : 2008, "foreignLanguage" : true, "fullPublication" : false, "published" : true, "snippet" : true }, "hasQualityFactor" : false, "link" : "/api/publication/26103545", "label" : "Colwell JA et al. Atherosclerosis and Thrombosis in Diabetes Mellitus: New Aspects of Pathogenesis. (2008) Megjelent: Levin and O'Neal's: The Diabetic Foot pp. 89-113", "template" : "